Zheng Quan Shi Bao Wang·2025-11-11 10:37Market Overview - A-share market closed with a total of 82 stocks hitting the daily limit, with 67 stocks after excluding 15 ST stocks, resulting in a limit-up rate of 70.09% [1] Stock Performance - Victory Shares had the highest limit-up order volume at 597,800 hands, followed by Xiexin Integrated, Conch New Materials, and Sanmu Group with order volumes of 567,600 hands, 305,800 hands, and 267,100 hands respectively [2] - ST Zhongdi achieved 18 consecutive limit-ups, while Moen Electric had 6 consecutive limit-ups, and several other stocks had multiple consecutive limit-ups [2] Sector Highlights Photovoltaic Sector - Key stocks that hit the limit include Guosheng Technology, Sanfu Shares, Jincheng Shares, Tuori New Energy, and Zhongli Group [3] - Guosheng Technology focuses on EPC business for photovoltaic power stations through bidding and strategic partnerships with large energy groups [3] - Sanfu Shares produces trichlorosilane, a key material for the photovoltaic industry, which is essential for manufacturing solar cells and modules [3] - Jincheng Shares is developing high-efficiency photovoltaic cell equipment, focusing on HJT and PERTOP technologies [3] Superhard Materials Sector - Stocks that hit the limit include Huanghe Xuanfeng, Sifangda, and Hengsheng Energy [4] - Huanghe Xuanfeng is expanding its production capacity and researching applications of diamond materials in various fields [4] - Sifangda benefits from rising tungsten prices, enhancing the competitiveness of its polycrystalline diamond composite products [4] - Hengsheng Energy is focused on diamond research and is expanding its production capacity, aiming for an annual output of 600,000 carats by the end of 2025 [4] Pharmaceutical Sector - Stocks that hit the limit include Renmin Tongtai, Jindike, Hefuchina, Te Yi Pharmaceutical, and Tailong Pharmaceutical [5] - Renmin Tongtai aims to establish a comprehensive healthcare service platform in Heilongjiang Province [6] - Jindike's R&D expenses increased due to the Phase III clinical trial of a quadrivalent influenza vaccine for children [6] - Hefuchina is investing in a digital medical audio-visual integration solution for surgical rooms [6] Institutional Activity - Institutions net bought over 100 million yuan in Sifangda, with other notable net purchases in Juhua Technology and Shangwei New Materials [7] - Specific institutional net purchases included 110 million yuan in Sifangda and 95 million yuan in Shengkong Shares [7]